scholarly article | Q13442814 |
P2093 | author name string | Aijaz Ahmed | |
Aparna Goel | |||
Christine Hong Ting Yang | |||
P2860 | cites work | Durability of sustained response shown in paediatric patients with chronic hepatitis C who were treated with interferon alfa-2b plus ribavirin. | Q50553046 |
Hepatitis C virus infection in children and adolescents. | Q54277218 | ||
Glecaprevir/pibrentasvir expands reach while reducing cost and duration of hepatitis C virus therapy | Q59360252 | ||
Chronic Hepatitis C Infection in Children | Q87924400 | ||
EASL Recommendations on Treatment of Hepatitis C 2016 | Q88412279 | ||
Daclatasvir: potential role in hepatitis C | Q27012741 | ||
Burden of pediatric hepatitis C | Q27025476 | ||
Small Interfering RNA Targeted to Hepatitis C Virus 5' Nontranslated Region Exerts Potent Antiviral Effect | Q27478036 | ||
Impact of Hepatitis C Virus Infection on Children and Their Caregivers: Quality of Life, Cognitive, and Emotional Outcomes | Q27487975 | ||
Diagnosis, management, and treatment of hepatitis C: an update | Q29619682 | ||
The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection | Q29620318 | ||
Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection | Q29620620 | ||
Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study | Q33435950 | ||
Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052 | Q34185949 | ||
Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study | Q36032750 | ||
Hepatitis B and C viruses in infants and young children | Q36279382 | ||
Allosteric inhibition of the hepatitis C virus NS5B RNA dependent RNA polymerase | Q36513118 | ||
Approaches to hepatitis C treatment and cure using NS5A inhibitors | Q37630422 | ||
Pediatric hepatitis C infection: to treat or not to treat...what's the best for the child? | Q37947635 | ||
NASPGHAN practice guidelines: Diagnosis and management of hepatitis C infection in infants, children, and adolescents | Q38001268 | ||
Hepatitis C virus proteins: from structure to function | Q38086751 | ||
Is genotype 3 of the hepatitis C virus the new villain? | Q38155123 | ||
New treatments for chronic hepatitis C: an overview for paediatricians | Q38282842 | ||
Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study | Q38445289 | ||
Hepatitis C in children in times of change | Q38551405 | ||
Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection | Q39058953 | ||
Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy | Q39415756 | ||
Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes | Q39421935 | ||
Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response | Q39449507 | ||
Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real-world cohort study | Q39481949 | ||
Increased Hepatitis C Virus (HCV) Detection in Women of Childbearing Age and Potential Risk for Vertical Transmission - United States and Kentucky, 2011-2014. | Q39576771 | ||
Response Tailored Protocol Versus the Fixed 12Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial. | Q39610676 | ||
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice. | Q39690146 | ||
Real-world effectiveness of ledipasvir/sofosbuvir in 4,365 treatment-naive, genotype 1 hepatitis C-infected patients | Q39821108 | ||
Treatment adherence and virological response rates in hepatitis C virus infected persons treated with sofosbuvir-based regimens: results from ERCHIVES. | Q39958110 | ||
Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study | Q40069100 | ||
Effectiveness of 8- or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naïve, genotype 1 hepatitis C infected patients. | Q40129813 | ||
Sofosbuvir and ribavirin in adolescents 12-17 years old with hepatitis C virus genotype 2 or 3 infection | Q40186025 | ||
Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study | Q40189279 | ||
Efficacy of Ledipasvir Plus Sofosbuvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2 Infection | Q40352957 | ||
The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12-17 years old with hepatitis C virus genotype 1 infection | Q40402518 | ||
Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients | Q40433082 | ||
Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection | Q40634052 | ||
Long-Term Follow-Up of Children Treated With Peginterferon and Ribavirin for Hepatitis C Virus Infection | Q40700593 | ||
Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: Analysis of phase III ION trials | Q40950331 | ||
Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection | Q41059944 | ||
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial | Q41343312 | ||
Health-Related Quality of Life in Adolescent Patients with Hepatitis C Genotype 1 Treated with Sofosbuvir and Ledipasvir | Q41928547 | ||
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. | Q43039677 | ||
Sofosbuvir/ledipasvir fixed-dose combination for treatment of chronic hepatitis C virus infection in children | Q45325089 | ||
The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period | Q45417690 | ||
Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients | Q46644977 | ||
Shortened 8 Weeks Course of Dual Sofosbuvir/Daclatasvir Therapy in Adolescent Patients, with Chronic Hepatitis C Infection. | Q46648340 | ||
Ledipasvir/Sofosbuvir: A Review in Chronic Hepatitis C. | Q47547989 | ||
The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. | Q47551548 | ||
Treatment of Chronic Hepatitis C Virus Infection in Children. A Position Paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. | Q47559718 | ||
Glecaprevir + pibrentasvir for treatment of hepatitis C. | Q49714606 | ||
Sofosbuvir/ledipasvir and ribavirin tolerability and efficacy in pediatric liver transplant recipients. | Q50267668 | ||
P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
P6216 | copyright status | copyrighted | Q50423863 |
P407 | language of work or name | English | Q1860 |
P921 | main subject | teenager | Q1492760 |
P304 | page(s) | 103-110 | |
P577 | publication date | 2018-01-01 | |
P1433 | published in | Adolescent Health, Medicine and Therapeutics | Q15816528 |
P1476 | title | Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C | |
P478 | volume | 9 |
Q91796536 | Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4 | cites work | P2860 |
Search more.